Finerenon

Martin Hausberg

doi:10.1055/a-1269-6670

Dialyse aktuell 2021; 25(03): 103-105
DOI: 10.1055/a-1269-6670

Expertentipp

Finerenon

Ein neuer selektiver nichtsteroidaler Mineralokortikoid-Rezeptor-Antagonist für die Behandlung der diabetischen Nephropathie

Martin Hausberg

Abstract

Die diabetische Nephropathie, eine Manifestation der diabetischen Mikroangiopathie, ist weiterhin die häufigste Ursache der terminalen dialysepflichtigen Niereninsuffizienz in den Industrienationen. Dies zeigen u. a. aktuelle Daten des Registers der „European Renal Association – European Dialysis and Transplant Association“ (ERA-EDTA) [1]. Die Pathophysiologie der diabetischen Nephropathie ist komplex. Wesentliche Progressionsfaktoren sind Hyperfiltration und Inflammation neben mangelhafter Kontrolle des Glukosestoffwechsels ([Abb. 2]).

Full Text

References

Literatur
1 Kramer A, Boenink R, Noordzij M. et al The ERA-EDTA Registry Annual Report 2017: a summary. Clin Kidney J 2020; 13: 693-709
2 Barnett A, Bain S, Bouter P. et al Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961
3 de Galan B, Perkovic V, Ninomiya T. et al Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20: 883-892
4 ADVANCE Collaborative Group Patel A, MacMahon S. et al Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
5 Wanner C, Inzucchi SE, Lachin JM. et al Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-334
6 Zinman B, Wanner C, Lachin JM. et al Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
7 Marso SP, Daniels GH, Brown-Frandsen K. et al Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322
8 Ito M, Tanaka T. The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors. Intern Med 2018; 57: 2105-2114
9 de Zeeuw D, Akizawa T, Audhya P. et al Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369: 2492-2503
10 Schjoedt KJ, Rossing K, Juhl TR. et al Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542
11 Schjoedt KJ, Rossing K, Juhl TR. et al Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836
12 Zuo C, Xu G. Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta-analysis. Int J Clin Pract. 2019 Aug 29 e13413
13 Dutzmann J, Musmann R-J, Haertlé M. et al The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PLoS One 2017; 12: e0184888
14 Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson AS. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone. Curr Cardiol Rep 2020; 22: 140
15 Bakris GL, Agarwal R, Anker SD. et al Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol 2019; 50: 333-344
16 Bakris GL, Agarwal R, Anker SD. et al Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383: 2219-2229
17 Perkovic V, Jardine MJ, Neal B. et al Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306